Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hisham Ashry

Podiatrist, Foot & Ankle Surgery Boynton Beach, FL Doctor of Podiatric Medicine

NPI 1285722884 CMS profile 330731

6609 Woolbright Rd Ste 416, Boynton Beach, FL 33437

Open in the dashboard

General payments

$144,697

510 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hisham Ashry of Boynton Beach, FL is reported in the CMS Open Payments database as having received $144,697 across 510 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,224 33
2024 General $26,205 58
2023 General $14,969 67
2022 General $26,635 89
2021 General $32,264 108
2020 General $15,114 43
2019 General $27,285 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hisham Ashry
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Hisham Ashry were reported at $2,224. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Hisham Ashry Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $27,285 $389 $118–$1,406 $163
2020 $15,114 $191 $62–$691 $114
2021 $32,264 $329 $104–$1,341 $132
2022 $26,635 $419 $125–$1,611 $149
2023 $14,969 $377 $128–$1,164 $160
2024 $26,205 $394 $134–$1,168 $164
2025 $2,224 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $125,615 261 payments
  2. Integra LifeSciences Corporation $2,958 39 payments
  3. Stryker Corporation $2,815 36 payments
  4. Treace Medical Concepts, Inc. $2,362 17 payments
  5. Medical Device Business Services, Inc. $1,554 5 payments
  6. Southern Edge Orthopaedics, Inc. $1,409 1 payment
  7. Organogenesis Inc. $1,025 31 payments
  8. Djo, LLC $724 11 payments
  9. Flower Orthopedics Coporation $697 11 payments
  10. TissueTech, Inc. $623 5 payments
  11. Other $4,914 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $86,579 41 payments
  2. Travel and Lodging $21,837 123 payments
  3. Food and Beverage $19,629 341 payments
  4. Consulting Fee $15,243 4 payments
  5. Education $1,409 1 payment
Products named General payments · program years 2019–2025
  1. COLLAGENASE SANTYL Pharma Products $36,756 67 payments
  2. COLLAGENASE SANTYL Pharma Product $20,355 40 payments
  3. REGRANEX $15,809 41 payments
  4. Santyl $14,509 40 payments
  5. GRAFIX PL $10,571 37 payments
  6. STRAVIX $10,335 34 payments
  7. GRAFIX $9,495 19 payments
  8. ALLEVYN LIFE L 15.4X15.4 CTN10 $8,869 5 payments
  9. PICO 7 $8,154 2 payments
  10. PICO $8,113 2 payments
  11. Other $72,526 526 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

195

Median for Podiatry: 160

Drug cost

$159,193

Median for Podiatry: $2,368

Branded share of claims

21.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 42 $156,838
Betamethasone Dipropionate Generic 11 $742
Lidocaine Generic 11 $725
Methylprednisolone Generic 94 $500
Gabapentin Generic 11 $200
Allopurinol Generic 12 $140
Meloxicam Generic 14 $47

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$515,912

Of which drugs: $394,040

Medicare patients

330

Average age 78

Services billed

2,615

195 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 44%
Ischemic heart disease 42%
Chronic kidney disease 40%
Atrial fibrillation 29%
Heart failure 25%
Osteoporosis 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 27 123 $81
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 27 144 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $157
$157 — —
JUBLIA
  • Ortho Dermatologics, a division of Bausch Health US, LLC $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

510 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record